CN Patent

CN106794177A — 治疗癌症的方法

Assigned to Epizyme Inc · Expires 2017-05-31 · 9y expired

What this patent protects

本发明提供了在有需要的细胞或受试者中通过使该细胞接触或向该受试者给予治疗有效量的EZH2抑制剂来治疗或减轻表征为异常、误调或增加的Zeste同源物增强子2(EZH2)活性的病症的症状的方法，该病症例如免疫逃逸、癌细胞诱导的免疫功能障碍、降低的免疫应答、减弱的炎症、减少的主要组织相容性复合物(MHC)的表达、或癌症。

USPTO Abstract

本发明提供了在有需要的细胞或受试者中通过使该细胞接触或向该受试者给予治疗有效量的EZH2抑制剂来治疗或减轻表征为异常、误调或增加的Zeste同源物增强子2(EZH2)活性的病症的症状的方法，该病症例如免疫逃逸、癌细胞诱导的免疫功能障碍、降低的免疫应答、减弱的炎症、减少的主要组织相容性复合物(MHC)的表达、或癌症。

Drugs covered by this patent

Patent Metadata

Patent number
CN106794177A
Jurisdiction
CN
Classification
—
Expires
2017-05-31
Drug substance claim
No
Drug product claim
No
Assignee
Epizyme Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.